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Intravenous Regional Anesthesia With 0.5% 
Articaine, 0.5% Lidocaine, or 0.5% Prilocaine
A Double-blind Randomized Clinical Study
M. A. M. Simon, M.D.,* M. J. M. Gielen, Ph.D.,+ 
N. Alberink,* T. B. Vree, Ph.D.,§ and J. van Egmond, Ph.D.t
Background and Objectives. The purpose  of this study was to com pare  the  effectiveness 
of three local anesthetic  agents for in travenous regional anesthesia in the upper 
limb, Side effects and plasm a concentrations of the drugs in  the doses adm inistered  
for IVRA w ere  also studied. Methods. Thirty patients in ASA groups I and  II received 
intravenous regional anesthesia  for surgery of the upper limb. In  a double-b lind  
prospective study, they  w ere  random ly  allocated to receive one of th ree  local a n e s ­
thetics: articaine, lidocaine, o r prilocaine. Patients received 40 mL of a 0.5%  so lu ­
tion of the local anesthetic . The onset lime of sensory block was assessed by p in ­
prick and the  ex ten t of m o to r  block was was scored as 0-3. Plasma concentra tions 
of local anesthetics w ere  d e te rm in ed  in all patients from serial arterial blood sam ­
ples drawn at p rede te rm ined  times before and after tourn iquet release. Results. The 
onset time of sensory block was significantly shorter (2.5 m inutes) in the articaine 
group than in the  lidocaine g roup  (11.1 m inutes) or th e  prilocaine group (10.9 m in ­
utes) (Scheffe, P < .05). D evelopm ent of m otor block was equal in all th ree  groups 
(score 2). Estim ation of p lasm a concentrations by high perfo rm ance liquid ch ro ­
m atography show ed th a t the  peak  level in all 30 patients was reached  im m ediately  
after release of the  to u rn iq u e t;  plasma concentrations thereafter gradually  declined. 
M aximum concen tra tions of articaine, lidocaine, and prilocaine were, 1.85, 8.5, and 
4.4 pg/mL, respectively. No signs of local anesthetic  toxicity of the  cardiovascular or 
central nervous systems w ere  seen. Conclusion. Articaine had the  fastest onset of 
sensory block and  the  lowest peak  plasma concentration of the th ree  local a n e s th e t­
ics w hen  used for in trav eno us  regional anesthesia. Reg Anesth 1997:22:29-34 .
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Intravenous regional anesthesia (IVRA), first 
described by Bier (1) in 1908, remains a popular 
technique for brief operations in the hand and fore-
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arm and to a lesser extent in the lower limb, espe­
cially w hen a tourniquet is applied for surgical indi­
cations. Good surgical anesthesia can be achieved 
rapidly following injection of the local anesthetic 
agent, and after release of the tourniquet, recovery 
is fast. This makes it a very useful technique for 
ambulatory surgery. The technique is generally safe 
(2), although complications resulting from technical 
failure (3,4) or the choice of an unsuitable local 
anesthetic agent have been reported. Bupivacaine, 
for example, is contraindicated because of its high 
potential for cardiotoxicity. In the Netherlands the 
two most frequently used local anesthetics for IVRA
*
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are lidocaine 0.5% and prilocaine 0.5%. Recently 
we introduced articaine 0.5% for IVRA in our clinic 
and experienced good clinical results.
The present report describes a double-blind 
prospective study, in  which we compared the onset 
time of sensory and motor block and possible side 
effects and complications of articaine 0.5%, lido­
caine 0.5%, and prilocaine 0.5% in IVRA, Plasma 
concentrations of local anesthetic were determined 
from arterial blood samples taken at regular intervals 
in order to investigate possible relationships between 
systemic blood levels and eventual toxic reactions.
Materials and Methods
The study was approved by the ethics committee 
of our hospital, and written informed consent was 
obtained from 30 patients (ASA classes and II), 
w ho were scheduled for surgery of the hand  or 
forearm. Our pharmacist, who did no t directly p a r­
ticipate in the trial, prepared a randomization table 
containing 30 num bers of which 10 were desig­
nated articaine, 10 lidocaine, and 10 prilocaine. 
Each of the 30 patients received a num ber chosen 
at random an d  th en  received a local anesthetic 
solution corresponding to tha t num ber. Neither the 
patient nor the anesthesiologist had  any k n o w l­
edge of the identity  of the solution, so that the 
double-blind n a tu re  of the trial was ensured. The 
groups were subsequently identified as articaine, 
lidocaine, and prilocaine.
No prem edication was given. An 18-gauge can­
nula  was introduced into a suitable vein in the dor­
sum  of the h an d  of the  arm  to be treated. A similar 
cannula was in troduced into a suitable vein in  the 
o ther arm, and  the radial artery of that arm was 
cannulated for continuous invasive blood pressure 
m onitoring and  in term itten t blood sampling.
Oxygen saturation via a Datex Satlite pulse oxi­
m eter (Datex, Division of Instrumentation Corp., 
Helsinki, Finland), three-lead electrocardiography, (I,
II, and HI via HP 78353 B) (Hewlett Packard, 
Andover, MA), pulse rate, and continuous invasive 
arterial blood pressure were monitored from the 
time of the first venous cannulation until withdrawal 
of the final blood sample. A 12-lead electrocardio­
gram (ECG) was registered on a Hellige Multiscriptor 
E.K. (Hellige, Freiburg, Germany) 33 in all patients 
before injection of the  local anesthetic agent and 5 
and 15 minutes after deflation of the tourniquet.
The arm w as exsanguinated by means of an 
Esmarch bandage, after which a pneum atic to u rn i­
quet, placed a round  the arm above the elbow was 
inflated to 150 m m  Hg above norm al systolic p res­
sure or to 300 m m  Hg, whichever was higher. A rti­
caine 0.5% (Ultracaine©) was obtained from 
Hoechst Pharmaceuticals (Frankfurt a M. Ger­
m any), prilocaine 0.5%, (Citanest) was obtained 
from Astra Pharmaceuticals (Rijswijk, the Nether­
lands), and lidocaine 0.5% was prepared by the pro­
duction unit of the Department of Pharmacy of the 
Medisch Spectrum Twente, the Netherlands, as 
described in the Formulary of Dutch Pharmacists (5) 
and  complied with the recommendations for lido­
caine hydrochloride injection published in the U.S. 
Pharmacopoeia, 23rd edition (6). A total of 40 mL 
of the allocated local anesthetic solution was 
injected over a period of 30 seconds. Skin reactions 
or subjective complaints were noted. The develop­
m en t of sensory block over the distributions of the 
m edian, radial, and ulnar nerves was assessed by 
pinprick. Motor block was assessed on a scale of 0 
to 3, as defined below:
0, No m otor block at all
1, No pronation/supination of forearm possible, 
bu t wrist and finger movements present
2, No pronation/supination of forearm possible 
and no wrist movem ents but finger m ove­
m ents present
3, No m ovem ent at all of the upper extremity
The onset of surgical analgesia was defined as 
the  period  from the end of the injection of the local 
anesthetic  to the loss of pinprick sensation in the 
distribution of all three nerves.
Arterial blood samples were taken before injec­
tion, 10 minutes after injection, and then at 10- 
m inu te  intervals until the tourniquet was released; 
thereafter blood samples were drawn at intervals of
1, 5, 10, 15, 20, 25, 30, 45, 60, 75, and 90 minutes. 
In no case was the tourniquet released within 30 
m inutes of completing the injection, even when 
actual surgery was of less than half-hour duration. 
The blood samples were centrifuged, and the plasma 
was frozen and stored at -20°C until analyzed.
Analysis
The concentrations of lidocaine or prilocaine were 
determ ined by high-performance liquid chrom ato­
graphy as described by Lindberg and Pillilajmaki (7) 
and th a t of articaine by high-performance liquid 
chromatography as described by Vree et al. (8). The 
day-to-day coefficient of variance for articaine, lido­
caine, and  prilocaine was 1.5%, 5.1%, and 6.1%, 
respectively. ‘
Statistics
All data were entered into a database and an a ­
lyzed by SAS statistical procedures (SAS Institute,
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Cary NC) on a personal computer. Group m eans 
were compared in a one-way analysis of variance 
followed by Scheffe's procedure to detect in te r­
group significance. Chi-square analysis was used in 
incidence tables. In all tests, P = .05 was used as the 
level of significance.
Results
Patient demographic data are listed in Table 1. 
The three groups were of comparable age and 
weight. The m ean onset time of surgical analgesia 
determined in this study was 2.5 minutes for arti­
caine, 11.2 minutes for lidocaine, and 10.9 m inutes 
for prilocaine (Table 2). The onset of surgical an a l­
gesia in the articaine group was significantly faster 
than in the lidocaine and prilocaine group (by the 
Scheffe procedure).
In all but two patients, (one in the lidocaine and 
one in the prilocaine group), satisfactory surgical 
conditions, evidenced by good sensory block, were 
reached within 20 minutes, and no additional 
analgesics were required. In order to include these 
two patients in the statistical calculations, their 
onset time was set arbitrarily at 20 minutes, 
although surgery could only be commenced after 
local infiltration of lidocaine 1%. There was no 
trend toward a fixed sequence for the developm ent 
of sensory block in the radial, median, and u lnar 
nerves. Motor block was incomplete in all 30 
patients (a score of 2 on the 0-3 scale), but patients 
were subjectively unaware of this.
None of the patients exhibited objective sym p­
toms of toxicity, either local or systemic, during 
injection of the local anesthetic, nor were there  
any subjective complaints. No changes in blood
pressure, heart rate, or oxygen saturation were 
observed at any time during the procedure and 
after deflation of the tourn iquet. Toxic symptoms 
and subjective complaints were similarly absent 
following cuff release, and no changes were 
recorded on the ECG in any of the  12 leads.
M ean plasma concentrations of the three local 
anesthetic agents at various times after cuff release 
are show n in Figure 1. Peak plasma concentrations 
were reached im m ediately after release of the 
tourniquet. Lidocaine exhibited the highest plasma 
concentration curve and articaine the lowest. M ax­
im um  concentrations of articaine, lidocaine, and 
prilocaine were 1.85, 8.5, and 4.4 |ag/mL respec­
tively, Local anesthetic was not detected in the 
plasma samples before cuff release in any of the 30 
patients.
Discussion
Articaine is a local anesthetic of the am inoam ide 
type, w hich differs from other local anesthetics in 
possessing a th iophene instead of a benzene ring 
(Fig. 2). Articaine was introduced by Hoechst Phar­
maceuticals in 1974. Early experim ents in the iso­
lated frog sciatic nerve model by M uschaweck and 
Rippel (9). dem onstrated an anesthetic potency 1.5 
times tha t of lidocaine. Its efficacy in topical anes­
thesia was low, but it was significantly superior to 
lidocaine for infiltration anesthesia. Since introduc­
tion, articaine has become popular, especially in 
eastern European countries, for central as well as 
peripheral neural block. Until recently its use in 
the Netherlands was restricted to dental proce­
dures; however, the last 5 years it has begun to be 
used by Dutch anesthesiologists as well (10,11).
T able  1. D em ograph ic  Dala for the  P a tien ts  in the  T hree  Local A nesthe tic  G roups
Anesthetic Men Women Age (y) (Mean ± SD) Weight (kg) (Mean ± SD)
Articaine 3 7 50.2 ± 14.2 70.5 ± 8.4
Lidocaine 3 7 42.6 ± 12.8 72.9 ± 12.5
Prilocaine 4 6 44.1 ±14.2 80.1 ± 15.7
T able  2. M ean O nset Times of Surgical A nalgesia  M easu red  in the
Three Local A nesthetic  G roups
Articaine Lidocaine Prilocaine
Onset time (min) ± SD 2.5 ± 1.07 1 1.2 ± 5.12 10.9 ±6.01
Scheffe grouping* A B B
*Only differences between Scheffe groups A and B are statistically significant.











minutes after cuff release
60 80 100
Fig. 1. Graphical presentation of the course of the m ean  local anesthetic  plasma concentration. Bars represent standard 
deviation.
Hendolin and Mattila (12) and Baeder et al. (13) 
reported a relatively low incidence of side effects, 
and van Oss (14) also showed that large doses do 
not elicit toxic reactions.
The physicochemical properties of articaine, lido­
caine, and prilocaine are listed in Table 3. These data
offer no convincing explanation for the faster onset 
time of articaine. There is very little difference 
betw een the pKa's of the three drugs, while the lipid 
solubility of articaine is lower than that of lidocaine 
or prilocaine. The vasodilatory effects of the three 
drugs are similar (9). Therefore, the more rapid
Fig. 2. Molecular structure ol lidocaine, prilocaine, and  articaine
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Table 3. Physicochemical Properties of Lidocaine, Prilocaine, and Articaine
Anesthetic
Molecular
Weight pK a Protein binding (%)
Lipid Solubility 
(log oct)*
Lidocaine 234.0 7.9 65 1.67
Prilocaine 220.0 7.9 55 1.31
Articaine 284.4 7.8 50-70 1.23
*Log oct (octanol) is the logarithm of the distribution ratio in a phase system where octanol and a buffer 
with pH 7.4 are used, A higher ratio reflects a better lipid solubility, Lidocaine and prilocaine pka from 
Tucker and Mather (25), articaine pka from Karzel (26), and lipid solubility data from Hansch and Leo (27).
onset time of articaine, as found in this study, can­
not be explained on the basis of physicochemical 
differences.
The question remains: Did we use equipotent 
doses? Muschaweck und Rippel (9) derived their 
data from the isolated frog sciatic nerve model, b u t 
data obtained from this source m ay no t be valid in 
vivo. Covino and Vassallo (15) no te  that while the 
intrinsic potency of chloroprocaine is four times 
that of procaine, in vivo the tw o drugs are equipo­
tent. Similarly, the intrinsic potency of lidocaine 
has been shown to be 1.5 times to twice that of 
mepivacaine and prilocaine, bu t again, in vivo the 
agents appear to be equipotent. In spite of the find­
ings of Muschaweck and Rippel (9), several clinical 
studies have shown articaine, prilocaine, and 
lidocaine to be equipotent in vivo. Hecksher-S0ren- 
sen (16), for example, was unable to demonstrate 
any clinical difference between 30 mL 1% lido­
caine and 30 mL 1% articaine w hen  used for 
brachial plexus block via the axilla. Reng and 
Auberger (17) reached the same conclusion w hen 
comparing 1 % lidocaine plus epinephrine with 1 % 
articaine plus epinephrine in epidural blocks for 
obstetric and gynecologic procedures. Hendolin 
and Mattila (12) and Brinklov (18) also compared 
lidocaine and articaine during epidural anesthesia 
and apart from a longer duration of action of a rti­
caine, found no significant clinical difference 
between the two drugs. Eerola and  Eerola (19) 
compared 2% solutions of articaine and prilocaine 
during epidural anesthesia and were similarly 
unable to demonstrate any significant difference in 
their anesthetic properties.
If, as stated by Lagermann et al. (20), the parti­
tion coefficient is a predictor of local anesthetic 
potency in the subarachnoid model, articaine 
should be the least potent drug. Covino and Vas­
sallo (15) also referred to this correlation betw een 
partition coefficient and local anesthetic potency, 
but there are conflicting reports in clinical studies, 
and no consistent in vivo picture emerges*
Two studies, one in rats (21) an d  the other in 
humans (22), failed to reveal a significant differ­
ence in potency betw een prilocaine and articaine. 
On the  basis of this w ork and the above-cited litera­
ture reports, we are led to the conclusion that 
despite M uschaweck and Rippel's findings (9),the 
drugs we investigated are equally po ten t in vivo. 
Despite apparent equivalence in dosage, we 
observed a faster onset time w hen  articaine was 
used. Similarly, Eerola (23) show ed that onset of 
analgesia in IVRA was m ore rapid w ith articaine 
th an  w ith prilocaine, although the quantitative dif­
ference in his series was less m arked than in ours. 
The low plasma levels of articaine may be explained 
by rapid hydrolysis to its 2-carboxy metabolite by 
plasma esterase activity (8). A lthough our plasma 
determ inations produced values that were higher 
th an  those of Brader et al (24) the results are not 
directly comparable because they used a different 
m ethod.
On the  basis of our results we conclude that arti­
caine has a significantly faster onset than  either 
prilocaine or lidocaine in IVRA.
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